Regal Investment Advisors LLC Sells 965 Shares of Merck & Co., Inc. (NYSE:MRK)
Regal Investment Advisors LLC Sells 965 Shares of Merck & Co., Inc. (NYSE:MRK)
Regal Investment Advisors LLC cut its holdings in shares of Merck & Co., Inc. (NYSE:MRK – Get Rating) by 7.1% during the 1st quarter, Holdings Channel reports. The firm owned 12,559 shares of the company's stock after selling 965 shares during the period. Regal Investment Advisors LLC's holdings in Merck & Co., Inc. were worth $1,030,000 as of its most recent filing with the Securities and Exchange Commission.
据Holdings Channel报道，富豪投资顾问公司在第一季度减持了默克公司(Merck&Co.，Inc.)股票7.1%。该公司在此期间出售了965股后，持有该公司12,559股股票。截至最近提交给美国证券交易委员会的文件，富豪投资顾问公司持有的默克公司股份价值1030,000美元。
Other hedge funds have also added to or reduced their stakes in the company. Bromfield Sneider Wealth Advisors bought a new position in Merck & Co., Inc. in the first quarter valued at approximately $79,000. Hikari Power Ltd grew its stake in shares of Merck & Co., Inc. by 5.0% during the first quarter. Hikari Power Ltd now owns 23,630 shares of the company's stock worth $1,939,000 after buying an additional 1,130 shares during the last quarter. ACG Wealth grew its stake in shares of Merck & Co., Inc. by 5.6% during the first quarter. ACG Wealth now owns 13,523 shares of the company's stock worth $1,110,000 after buying an additional 722 shares during the last quarter. Mascoma Wealth Management LLC grew its stake in shares of Merck & Co., Inc. by 36.4% during the first quarter. Mascoma Wealth Management LLC now owns 926 shares of the company's stock worth $76,000 after buying an additional 247 shares during the last quarter. Finally, WealthBridge Investment Counsel Inc. lifted its holdings in shares of Merck & Co., Inc. by 4.1% during the first quarter. WealthBridge Investment Counsel Inc. now owns 87,820 shares of the company's stock worth $7,206,000 after purchasing an additional 3,475 shares during the period. 72.88% of the stock is owned by institutional investors.
其他对冲基金也增持或减持了该公司的股份。Bromfield Sneider Wealth Advisors在第一季度购买了默克公司的一个新头寸，价值约7.9万美元。Hikari Power Ltd在第一季度增持了默克公司的股票5.0%。Hikari Power Ltd现在拥有23,630股该公司股票，价值1,939,000美元，此前该公司在上个季度又购买了1,130股。今年第一季度，ACG Wealth在默克公司(Merck&Co.，Inc.)的持股增加了5.6%。ACG Wealth现在拥有13,523股该公司股票，价值1，11万美元，在上个季度又购买了722股。Masoma Wealth Management LLC在第一季度增持了默克公司(Merck&Co.，Inc.)股票36.4%。Mascoma Wealth Management LLC现在持有该公司926股股票，价值7.6万美元，上个季度又购买了247股。最后，WealthBridge Investment Counsel Inc.在第一季度增持了4.1%的默克公司股票。WealthBridge Investment Counsel Inc.在此期间又购买了3,475股，目前持有87,820股该公司股票，价值7,206,000美元。72.88%的股份由机构投资者持有。
Merck & Co., Inc. Price Performance
默克公司性价比
Shares of NYSE:MRK opened at $87.41 on Friday. The company's fifty day moving average price is $90.27 and its 200-day moving average price is $85.38. The firm has a market capitalization of $221.04 billion, a price-to-earnings ratio of 13.39, a PEG ratio of 1.17 and a beta of 0.32. Merck & Co., Inc. has a one year low of $70.89 and a one year high of $95.72. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.40 and a quick ratio of 1.14.
纽约证券交易所股票：Mr K上周五开盘报87.41美元。该公司的50日移动均线价格为90.27美元，200日移动均线价格为85.38美元。该公司市值为2,210.4亿美元，市盈率为13.39倍，聚乙二醇率为1.17倍，贝塔系数为0.32。默克公司的一年低点为70.89美元，一年高位为95.72美元。该公司的债务权益比为0.75，流动比率为1.40，速动比率为1.14。
Merck & Co., Inc. Announces Dividend
默克公司宣布分红
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be issued a dividend of $0.69 per share. This represents a $2.76 annualized dividend and a dividend yield of 3.16%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.'s dividend payout ratio is currently 42.27%.
该公司最近还宣布了季度股息，将于10月7日(星期五)支付。9月15日(星期四)登记在册的投资者将获得每股0.69美元的股息。这意味着年化股息为2.76美元，股息收益率为3.16%。本次股息除息日为9月14日星期三。默克公司目前的股息支付率为42.27%。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
A number of brokerages have recently commented on MRK. Atlantic Securities lifted their price target on shares of Merck & Co., Inc. from $105.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, July 13th. Morgan Stanley lifted their price target on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an "equal weight" rating in a report on Friday, July 29th. SVB Leerink reiterated an "outperform" rating and set a $102.00 price target on shares of Merck & Co., Inc. in a report on Monday, June 6th. Cowen boosted their target price on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the company a "market perform" rating in a report on Monday, June 27th. Finally, Barclays boosted their target price on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the company an "overweight" rating in a report on Tuesday, April 12th. Eight investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $97.44.
近期多家券商纷纷对MRK发表评论。大西洋证券将默克公司的股票目标价从105.00美元上调至110.00美元，并在7月13日周三的一份报告中给予该股“增持”评级。摩根士丹利在7月29日星期五的一份报告中将默克公司的股票目标价从88.00美元上调至92.00美元，并给予该股“同等权重”的评级。SVB Leerink在6月6日周一的一份报告中重申了对默克公司的评级，并为默克公司的股票设定了102.00美元的目标价。考恩在6月27日周一的一份报告中将默克公司股票的目标价从95美元上调至102.00美元，并给予该公司“市场表现”评级。最后，巴克莱在4月12日周二的一份报告中将默克公司股票的目标价从94.00美元上调至97.00美元，并给予该公司“增持”评级。8名投资分析师对该股的评级为持有，9名分析师给出了买入评级，两名分析师对该股发出了强烈的买入评级。根据MarketBeat的数据，该公司目前的共识评级为“适度买入”，共识目标价为97.44美元。
Merck & Co., Inc. Company Profile
默克公司公司简介
(Get Rating)
(获取评级)
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
默克公司是一家全球性的医疗保健公司。它通过两个部门运作，制药和动物健康。制药部门提供肿瘤学、医院急性护理、免疫学、神经科学、病毒学、心血管和糖尿病等领域的人类健康药物产品，以及疫苗产品，如预防性儿科、青少年和成人疫苗。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Merck & Co., Inc. (MRK)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- 免费获取StockNews.com关于默克公司的研究报告(MRK)
- MarketBeat：回顾中的一周8/1-8/5
- 如何利用高贝塔系数股票最大化你的投资利润
- 克罗诺斯集团(Cronos Group Inc.)营收上升，是时候收购了吗？
- 苹果为何可能在年底创下历史新高
- Beyond Meat不是没有希望，而且它很便宜
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Get Rating).
想看看还有哪些对冲基金持有MRK吗？访问HoldingsChannel.com获取默克公司(NYSE：MRK-GET Rating)的最新13F文件和内幕交易信息。
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到默克公司的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对默克公司和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。